GlassScriptPhysician profile
Deepali Nivas Tukaye
NPI 1730404120
$6,372.50
in general payments reported to CMS, 2019-2025
32 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,317 · 2020: $90.71 · 2021: $814 · 2022: $600 · 2023: $2,660 · 2024: $722 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265 · Travel and Lodging: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.98 |
| Travel and Lodging | $1,285.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,393.67 | 2022-2024 | Corevalve Evolut R, Venaseal |
| Novartis Pharmaceuticals Corporation | $679.55 | 2019-2025 | |
| Boston Scientific Corporation | $589.83 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device, Accolade Sr |
| Medtronic Vascular, INC. | $579.23 | 2019 | |
| Amgen INC. | $450.83 | 2019-2024 | Krystexxa |
| Inari Medical, INC. | $183.26 | 2021 | |
| Shockwave Medical, INC | $182.14 | 2021 | |
| Merck Sharp & Dohme LLC | $168.66 | 2021-2023 | Verquvo |
| Pfizer INC. | $138.35 | 2019-2020 | |
| Novo Nordisk INC | $117.29 | 2021-2024 | Ozempic, Rybelsus |
| Getinge USA Sales, LLC | $106.25 | 2021 | |
| Cardiovascular Systems INC. | $77.27 | 2019 | |
| Philips North America LLC | $75.00 | 2021 | |
| Esperion Therapeutics, INC. | $73.00 | 2021 | |
| Abbott Laboratories | $68.76 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $67.41 | 2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $60.13 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.82 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $41.98 | 2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $41.79 | 2019-2021 | |
| Edwards Lifesciences Corporation | $27.79 | 2023 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $27.59 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.94 | 2023 | Onpattro |
| Tactile Systems Technology INC | $26.02 | 2023 | Flexitouch Plus, Entre Plus |
| Regeneron Healthcare Solutions, INC. | $19.29 | 2019 | |
| Bracco Diagnostics INC. | $17.35 | 2023 | |
| Siemens Medical Solutions USA, INC. | $16.43 | 2019 | |
| Irhythm Technologies, INC. | $16.21 | 2023 | Zio Xt Patch |
| Cook Medical LLC | $15.98 | 2019 | |
| Biotronik INC. | $13.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$175,001.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepali Tukaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.